Cidara Therapeutics, Inc.
CDTXDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Rezafungin for Injection
Candidemia
CD101 Vaginal Gel (3%)
Candidiasis, Vulvovaginal
CD101
Candidemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rezafungin for Injection | Phase 3 | Candidemia | - | - |
CD101 Vaginal Gel (3%) | Phase 2 | Candidiasis, Vulvovaginal | - | - |
CD101 | Phase 2 | Candidemia | - | - |
Frequently asked questions
What is in Cidara Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cidara Therapeutics, Inc.'s (CDTX) pipeline across Phase 3, Phase 2. Its lead program is Rezafungin for Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cidara Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cidara Therapeutics, Inc. (CDTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CDTX biotech catalysts?→
Add CDTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cidara Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.